[go: up one dir, main page]

PT2773325T - Corticosteróides lipossômicos para o tratamento de transtornos inflamatórios em humanos - Google Patents

Corticosteróides lipossômicos para o tratamento de transtornos inflamatórios em humanos

Info

Publication number
PT2773325T
PT2773325T PT12788306T PT12788306T PT2773325T PT 2773325 T PT2773325 T PT 2773325T PT 12788306 T PT12788306 T PT 12788306T PT 12788306 T PT12788306 T PT 12788306T PT 2773325 T PT2773325 T PT 2773325T
Authority
PT
Portugal
Prior art keywords
humans
treatment
inflammatory disorders
liposomal
corticosteroids
Prior art date
Application number
PT12788306T
Other languages
English (en)
Inventor
Maarten Metselaar Josbert
Original Assignee
Enceladus Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enceladus Pharmaceuticals B V filed Critical Enceladus Pharmaceuticals B V
Publication of PT2773325T publication Critical patent/PT2773325T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT12788306T 2011-11-04 2012-11-02 Corticosteróides lipossômicos para o tratamento de transtornos inflamatórios em humanos PT2773325T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NLPCT/NL2011/050755 2011-11-04

Publications (1)

Publication Number Publication Date
PT2773325T true PT2773325T (pt) 2018-12-19

Family

ID=47215701

Family Applications (1)

Application Number Title Priority Date Filing Date
PT12788306T PT2773325T (pt) 2011-11-04 2012-11-02 Corticosteróides lipossômicos para o tratamento de transtornos inflamatórios em humanos

Country Status (13)

Country Link
US (2) US10471010B2 (pt)
EP (1) EP2773325B1 (pt)
JP (2) JP2014532697A (pt)
CN (1) CN104144679A (pt)
AU (1) AU2012331702B2 (pt)
CA (1) CA2854430C (pt)
DK (1) DK2773325T3 (pt)
ES (1) ES2701748T3 (pt)
IN (1) IN2014MN00887A (pt)
PL (1) PL2773325T3 (pt)
PT (1) PT2773325T (pt)
TR (1) TR201818978T4 (pt)
WO (1) WO2013066179A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160101124A1 (en) * 2014-10-13 2016-04-14 King Abdullah International Medical Research Center Nano-liposomal aminoglycoside-thymoquinone formulations
EP3349729A4 (en) * 2015-09-14 2019-06-26 VGSK Technologies, Inc. STERILE-STABILIZED CARRIER FOR SUBCUTANEOUS, SUB-LINGUAL AND ORAL THERAPEUTICS, COMPOSITIONS AND METHOD FOR TREATING ANIMALS
JP7017018B2 (ja) * 2015-11-10 2022-02-08 チルドレンズ リサーチ インスティテュート、チルドレンズ ナショナル メディカル センター エキノマイシン製剤、その製造法および使用法
US20180360758A1 (en) * 2015-12-17 2018-12-20 Nanyang Technological University Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them
WO2017115358A1 (en) 2015-12-28 2017-07-06 Mb Biotech Ltd. Liposomes for treatment of an autoimmune disease
WO2017188818A1 (en) * 2016-04-29 2017-11-02 Enceladus Pharmaceuticals B.V. Liposomal corticosteroids for topical injection in inflamed lesions or areas
WO2018119413A1 (en) * 2016-12-22 2018-06-28 Lipidair, Llc Targeted delivery methods and compositions for antihistamines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE4341472A1 (de) * 1993-12-02 1995-06-08 Schering Ag Verfahren zur Erhöhung der Stabilität von hydrophile Wirkstoffe enthaltenden Liposomensuspensionen
AU4424797A (en) * 1996-09-18 1998-04-14 Dragoco Inc. Liposome encapsulated active agent dry powder composition
ES2260321T3 (es) * 2000-12-07 2006-11-01 Universiteit Utrecht Holding B.V. Composicion para el tratamiento de transtornos inflamatorios.
EP1490044A4 (en) * 2002-03-29 2008-04-16 Neurogen Corp COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMABLE COMPONENTS
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
DE10255106A1 (de) * 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
US20060115523A1 (en) 2004-12-01 2006-06-01 Konduri Kameswari S Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
WO2005072290A2 (en) * 2004-01-23 2005-08-11 Joslin Diabetes Center Methods of treating, reducing, or preventing autoimmune conditions
EP1727557A1 (en) * 2004-03-26 2006-12-06 Charite-Universitätsmedizin Berlin Uses of galectin-2
US8119156B2 (en) * 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2009052293A1 (en) * 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
AU2009246870B2 (en) * 2008-05-14 2013-08-01 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
EP2127639A1 (en) 2008-05-26 2009-12-02 Universiteit Utrecht Holding B.V. Corticosteroid containing liposomes for treatment of cardiovascular diseases

Also Published As

Publication number Publication date
PL2773325T3 (pl) 2019-03-29
US20150050329A1 (en) 2015-02-19
US10471010B2 (en) 2019-11-12
JP2017214401A (ja) 2017-12-07
AU2012331702B2 (en) 2017-10-26
DK2773325T3 (en) 2019-01-14
CN104144679A (zh) 2014-11-12
EP2773325A1 (en) 2014-09-10
NZ625022A (en) 2016-06-24
AU2012331702A2 (en) 2014-05-22
JP6609286B2 (ja) 2019-11-20
CA2854430C (en) 2021-06-01
JP2014532697A (ja) 2014-12-08
IN2014MN00887A (pt) 2015-04-17
CA2854430A1 (en) 2013-05-10
TR201818978T4 (tr) 2019-01-21
WO2013066179A1 (en) 2013-05-10
EP2773325B1 (en) 2018-09-19
AU2012331702A1 (en) 2014-05-22
ES2701748T3 (es) 2019-02-25
US20200253871A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
ZA201305784B (en) Compositions and methods for treating chronic inflammation and inflammatory diseases
IL229582A0 (en) Antibodies against kir for the treatment of inflammatory disorders
ZA201308421B (en) Compositions uses and methods for treatment of metabolic disorders and diseases
IL226401A0 (en) Methods for treating disorders related to @fgfBA
HK1199015A1 (en) Treatment of inflammation
HK1208358A1 (en) Treatment of inflammatory disorders in non-human mammals
PL2668182T3 (pl) Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego
PL2668183T3 (pl) Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego
SG11201401202YA (en) Antagonists of il17c for the treatment of inflammatory disorders
EP2723347A4 (en) PREVENTING AND TREATING INFLAMMATORY DISEASES
PL2773325T3 (pl) Liposomalne kortykosteroidy w leczeniu chorób zapalnych u istot ludzkich
GB201202773D0 (en) Compositions for treatment of skin disorders
EP2544703A4 (en) METHODS OF TREATING VASCULAR INFLAMMATORY DISORDERS
HK1204573A1 (en) Treatment of inflammatory skin disorders
IL232710A0 (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
HK1205522A1 (en) Methods of treating inflammatory disorders using anti-m-csf antibodies m-csf
HK1186986A1 (zh) 治療皮膚病的方法
EP2854784A4 (en) METHOD OF TREATING INFLAMMATORY SKIN DISEASES
EP2838508A4 (en) Formulations and methods for the treatment of acne and inflammatory skin diseases
IL223385B (en) Treatment of inflammatory disorders
GB201217330D0 (en) Therapeutic for treating inflammatory lung disorders
EP2734634A4 (en) TREATMENT OF MIGRAINE AND RELATED DISEASES
ZA201408045B (en) Compositions and methods for the treatment of inflammation and lipid disorders
GB201101773D0 (en) Treatment of inflammatory disorders
IL227921A0 (en) Methods for prognosis and treatment of inflammatory disorders